Hengrui Medicine (01276): HRS-5346 tablets approved to initiate clinical trials

Zhitong Finance APP news, Hengrui Pharmaceuticals (01276) announced that recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for HRS-5346 tablets, and will commence clinical trials in the near future.